Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Karissa Johnston, Jayson M Stoffman, Alexis T Mickle, Robert J Klaassen, Demitri Diles, Shade Olatunde, Lina Eliasson & Roxana Bahar. (2021) Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample. Patient Preference and Adherence 15, pages 1407-1417.
Read now
Read now
Zohreh Zahedi, Mehran Karimi, Khosro Keshavarz, Sezaneh Haghpanah & Ramin Ravangard. (2021) A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran. Hematology 26:1, pages 240-248.
Read now
Read now
Bernd Tischer, Renato Marino & Mariasanta Napolitano. (2018) Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Preference and Adherence 12, pages 431-441.
Read now
Read now
Articles from other publishers (17)
Irena Preloznik Zupan, Karla Rener & Sasa Anzej Doma. (2022) Treatment satisfaction and limitations in haemophilia A, with a focus on factor VIII product storage conditions: patients’ perspectives and challenges. Drugs & Therapy Perspectives 39:2, pages 71-80.
Crossref
Crossref
John Spoors, Alec Miners & John Cairns. (2022) Discrete choice experiments: An overview of experience to date in haemophilia. The Journal of Haemophilia Practice 9:1, pages 50-63.
Crossref
Crossref
Alisha Monnette, Er Chen, Dongzhe Hong, Alessandra Bazzano, Stacy Dixon, W. David Arnold & Lizheng Shi. (2021) Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Young Shil Park, Tai Ju Hwang, Goon Jae Cho, Soon Ki Kim, Sang Kyu Park, Ji Yoon Kim, Hee Jo Baek, Young‐Joo Kim, Ho‐Jin Lee, Ji‐Soo Shin, Chung‐Mo Nam, Jiyu Sun & Ki Young Yoo. (2021) Patients’ and parents’ satisfaction with, and preference for, haemophilia A treatments: a cross‐sectional, multicentre, observational study. Haemophilia 27:4, pages 563-573.
Crossref
Crossref
Melody Benton, Anisha M. Patel, Lizheng Shi, Alisha Monnette, Dongzhe Hong, Rebecca Kruse‐Jarres & Karina Raimundo. (2020) Assessing patient and caregiver preferences for treatment of haemophilia A: A discrete choice experiment. Haemophilia 27:4.
Crossref
Crossref
Eline van Overbeeke, Brett Hauber, Sissel Michelsen, Michel Goldman, Steven Simoens & Isabelle Huys. (2021) Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia. Frontiers in Medicine 8.
Crossref
Crossref
Eline Overbeeke, Sissel Michelsen, Brett Hauber, Kathelijne Peerlinck, Cedric Hermans, Catherine Lambert, Michel Goldman, Steven Simoens & Isabelle Huys. (2020) Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study. Haemophilia 27:1, pages 129-136.
Crossref
Crossref
Jun Su, Nanxin Li, Namita Joshi, Xinyi Ng, Marc Botteman, Rachel Shah, Nisha Jain, Nicole Lyn & Ronald Preblick. (2020) Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment. Haemophilia 26:6.
Crossref
Crossref
Million A. Tegenge, Artur Belov, Megan Moncur, Richard Forshee & Telba Irony. (2020) Comparing clotting factors attributes across different methods of preference elicitation in haemophilia patients. Haemophilia 26:5, pages 817-825.
Crossref
Crossref
Jayashree Motwani, Benoit Guillet, Jan Blatny, Freimut H. Schilling, Bénédicte Wibaut, Jimena Goldstine, Andras Nagy, Jennifer Doralt, Werner Engl, Srilatha Tangada & Gerald Spotts. (2020) Postauthorization safety surveillance study of antihaemophilic factor (recombinant) reconstituted in 2 mL sterile water for injection in children with haemophilia A. Haemophilia 26:3, pages 478-486.
Crossref
Crossref
Debra Pollard, Kate Khair & Mike Holland. (2020) Experience of switching to NovoEight: views of people with haemophilia. The Journal of Haemophilia Practice 7:1, pages 70-77.
Crossref
Crossref
Jane R. Wells, Adam Gater, Chris Marshall, Theo Tritton, Parth Vashi & Sophia Kessabi. (2019) Exploring the Impact of Infusion Frequency in Hemophilia A: Exit Interviews with Patients Participating in BAY 94-9027 Extension Studies (PROTECT VIII). The Patient - Patient-Centered Outcomes Research 12:6, pages 611-619.
Crossref
Crossref
Kate Khair, Debra Pollard, Catherine Harrison, Susan Hook, Mike O’Driscoll & Michael Holland. (2019) HOw Patients view Extended half‐life products: Impressions from real‐world experience (The HOPE study). Haemophilia 25:5, pages 814-820.
Crossref
Crossref
Fadi Nossair & Courtney D. Thornburg. (2018) The role of patient and healthcare professionals in the era of new hemophilia treatments in developed and developing countries. Therapeutic Advances in Hematology 9:8, pages 239-249.
Crossref
Crossref
Victoria F. Wagner, Hope Northrup, S. Shahrukh Hashmi, Joanne M. Nguyen, Mary Kay Koenig & Jessica M. Davis. (2017) Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies. Journal of Genetic Counseling 27:1, pages 169-176.
Crossref
Crossref
Z. Li, J. Wu, Y. Zhao, R. Liu, K. Li, Y. Zhou, R. Wu, R. Yang, X. Zhang, S. Lian, Q. Hu, X. Li, J. Gu, R. Zhou, J. Sun, C. Li, W. Xu, M.-C. Poon & J. Xiao. (2018) Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China. Haemophilia 24:1, pages 126-133.
Crossref
Crossref
S. von Mackensen, W. Kalnins, J. Krucker, J. Weiss, W. Miesbach, M. Albisetti, I. Pabinger & J. Oldenburg. (2017) Haemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Haemophilia 23:4, pages 566-574.
Crossref
Crossref